SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Johnny Cash Synthetic CCD

PatientJohnny Cash
Date of birth1955-02-26
IdentifiersMRN HR-ML004-SYN; SSN (made up) 000-04-8125
Document date2026-11-01
AuthorGideon Hale, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Primary care new-patient visit for diabetes, lightheadedness on standing, and glaucoma follow-up. Concerns: Lightheaded when he stands and afraid of another fall; was once told he had Shy-Drager syndrome and wants to know what he really has; Wants to keep the sight he has left so he can keep writing songs. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin 500 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2024-05-06 to 2026-02-27completedS
Metformin 1000 mg oral tablet, one tablet by mouth twice daily with mealsOne tablet by mouth twice daily with mealsOral route2026-02-27activeS
Sitagliptin 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-27activeS
Atorvastatin 40 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-02-27activeS
Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtimeOne drop in each eye at bedtimeOphthalmic route2023-09-11activeS
Dorzolamide 2% ophthalmic solution, one drop in each eye twice dailyOne drop in each eye twice dailyOphthalmic route2026-02-27activeS
Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2026-03-27 to 2026-05-29completedS
Midodrine 5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PMOne tablet by mouth on waking, at midday, and mid-afternoon; last dose at least four hours before bedOral route2026-05-29activeS

Procedures

ProcedureDatesStatusEvidence
Comprehensive diabetic foot examination with 10-g monofilament and vibration testing2026-02-27 to 2026-02-27completedS
Optical coherence tomography of the optic nerve and retinal nerve fiber layer, both eyes2026-02-27 to 2026-02-27completedS
Dilated eye examination and Humphrey 24-2 visual field testing, both eyes2026-02-27 to 2026-02-27completedS
Optical coherence tomography of the optic nerve and retinal nerve fiber layer, both eyes2026-08-14 to 2026-08-14completedS
Humphrey 24-2 visual field testing, both eyes2026-08-14 to 2026-08-14completedS

Immunizations

DateVaccineStatusEvidence
2025-10-20High-dose influenza vaccine, 2025-2026 seasoncompletedS
2026-02-27Pneumococcal conjugate vaccine PCV20completedS
2026-05-29Recombinant zoster vaccine, dose 1completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1957Amphetamine use beginning in 1957, with barbiturates in the 1960s; addiction lasting about a decadeD (CLM-0004)
1983Hospitalized in 1983 with internal bleeding, followed by treatment at the Betty Ford ClinicD (CLM-0005)
October 1997Diagnosed with Shy-Drager syndrome in October 1997; he said in 2000 that it was a misdiagnosis, and autonomic neuropathy was later identifiedD (CLM-0006, CLM-0007)
February 2001Pneumonia treated at Baptist Hospital in Nashville in February 2001, one of several pneumonia admissionsD (CLM-0008)

Family History

RelativeConditionAge at deathEvidence
brotherOlder brother Jack died in a sawmill accident in 1944D (CLM-0003)

Health Concerns

ConcernStatusEvidence
Lightheaded when he stands and afraid of another fall; was once told he had Shy-Drager syndrome and wants to know what he really hasactiveS
Wants to keep the sight he has left so he can keep writing songsactiveS

Assessment

Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 7.3 on 2026-08-14; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-08-14; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-08-14; Creatinine [Mass/volume] in Serum or Plasma 1.05 on 2026-08-14; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 73 on 2026-08-14; Glucose [Mass/volume] in Serum or Plasma 131 on 2026-08-14; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 74 on 2026-05-29; Albumin/Creatinine [Mass Ratio] in Urine 16 on 2026-08-14; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 2026-05-29; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-02-27; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 286 on 2026-02-27; Thyrotropin [Units/volume] in Serum or Plasma 1.9 on 2026-02-27; Hemoglobin [Mass/volume] in Blood 13.8 on 2026-02-27; Right eye Intraocular pressure 14 on 2026-08-14; Left eye Intraocular pressure 15 on 2026-08-14; Right retina Retinal nerve fiber layer.mean thickness by OCT 60 on 2026-08-14; Left retina Retinal nerve fiber layer.mean thickness by OCT 57 on 2026-08-14; Visual acuity best corrected Right eye by ETDRS eye chart 68 on 2026-08-14; Visual acuity best corrected Left eye by ETDRS eye chart 62 on 2026-08-14; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-04-24; Total score [Mini-Cog] 5 on 2026-02-27; Total score [AUDIT-C] 0 on 2026-04-24 [S]

Strengths and supports: Supports: a family member who comes to visits and fills his pill organizer, and his church community [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intakeactiveconfirmed E11.43S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy.
Neurogenic orthostatic hypotension from diabetic autonomic neuropathyactiveconfirmed I95.1S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome.
Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feetactiveconfirmed E11.42S — Synthetic finding linked to his description of numb lower extremities.
Primary open-angle glaucoma, both eyes, severe stageactiveconfirmed H40.1133S — Synthetic modern diagnosis; the type and stage are not documented historically.
Mild nonproliferative diabetic retinopathy without macular edema, both eyesactiveconfirmed E11.3293S — Synthetic finding from the dilated eye examination.
Hyperlipidemiaactiveconfirmed E78.5S — Synthetic finding from the baseline LDL cholesterol.
History of recurrent pneumoniaactiveconfirmed Z87.01S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination.

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-27Hemoglobin A1c/Hemoglobin.total in Blood8.6%<=5.6%HighS
2026-02-27Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
2026-02-27Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
2026-02-27Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
2026-02-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M74mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-27Glucose [Mass/volume] in Serum or Plasma186mg/dL70-99 mg/dLHighS
2026-02-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation128mg/dL<=99 mg/dLHighS
2026-02-27Albumin/Creatinine [Mass Ratio] in Urine18mg/g<=30 mg/gNormalS
2026-02-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-56 U/LNormalS
2026-02-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L10-40 U/LNormalS
2026-02-27Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma286pg/mL232-1245 pg/mLNormalS
2026-02-27Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.45-4.5 mIU/LNormalS
2026-02-27Hemoglobin [Mass/volume] in Blood13.8g/dL13.2-16.6 g/dLNormalS
2026-02-27Right eye Intraocular pressure22mm[Hg]10-21 mmHgHighS
2026-02-27Left eye Intraocular pressure24mm[Hg]10-21 mmHgHighS
2026-02-27Right retina Retinal nerve fiber layer.mean thickness by OCT61um80-120 umLowS
2026-02-27Left retina Retinal nerve fiber layer.mean thickness by OCT57um80-120 umLowS
2026-02-27Visual acuity best corrected Right eye by ETDRS eye chart68{letters}>=80LowS
2026-02-27Visual acuity best corrected Left eye by ETDRS eye chart63{letters}>=80LowS
2026-02-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
2026-02-27Total score [Mini-Cog]5{score}S
2026-03-27Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-27Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
2026-03-27Creatinine [Mass/volume] in Serum or Plasma1.06mg/dL0.74-1.35 mg/dLNormalS
2026-03-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M72mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-03-27Glucose [Mass/volume] in Serum or Plasma152mg/dL70-99 mg/dLHighS
2026-05-29Hemoglobin A1c/Hemoglobin.total in Blood7.7%<=5.6%HighS
2026-05-29Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation74mg/dL<=99 mg/dLNormalS
2026-05-29Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L7-56 U/LNormalS
2026-05-29Right eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2026-05-29Left eye Intraocular pressure16mm[Hg]10-21 mmHgNormalS
2026-05-29Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-08-14Hemoglobin A1c/Hemoglobin.total in Blood7.3%<=5.6%HighS
2026-08-14Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
2026-08-14Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
2026-08-14Creatinine [Mass/volume] in Serum or Plasma1.05mg/dL0.74-1.35 mg/dLNormalS
2026-08-14Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M73mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-14Glucose [Mass/volume] in Serum or Plasma131mg/dL70-99 mg/dLHighS
2026-08-14Albumin/Creatinine [Mass Ratio] in Urine16mg/g<=30 mg/gNormalS
2026-08-14Right eye Intraocular pressure14mm[Hg]10-21 mmHgNormalS
2026-08-14Left eye Intraocular pressure15mm[Hg]10-21 mmHgNormalS
2026-08-14Right retina Retinal nerve fiber layer.mean thickness by OCT60um80-120 umLowS
2026-08-14Left retina Retinal nerve fiber layer.mean thickness by OCT57um80-120 umLowS
2026-08-14Visual acuity best corrected Right eye by ETDRS eye chart68{letters}>=80LowS
2026-08-14Visual acuity best corrected Left eye by ETDRS eye chart62{letters}>=80LowS
2026-04-24Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
2026-04-24Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-27Body height188cmS
2026-02-27Body weight96kgS
2026-02-27Body mass index (BMI) [Ratio]27.2kg/m2S
2026-02-27Systolic blood pressure146mm[Hg]S
2026-02-27Diastolic blood pressure80mm[Hg]S
2026-02-27Heart rate78/minS
2026-02-27Respiratory rate16/minS
2026-02-27Body temperature36.7CelS
2026-02-27Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-03-27Body height188cmS
2026-03-27Body weight95kgS
2026-03-27Body mass index (BMI) [Ratio]26.9kg/m2S
2026-03-27Systolic blood pressure142mm[Hg]S
2026-03-27Diastolic blood pressure78mm[Hg]S
2026-03-27Heart rate76/minS
2026-03-27Respiratory rate16/minS
2026-03-27Body temperature36.6CelS
2026-03-27Oxygen saturation in Arterial blood by Pulse oximetry95%S
2026-05-29Body height188cmS
2026-05-29Body weight93.5kgS
2026-05-29Body mass index (BMI) [Ratio]26.5kg/m2S
2026-05-29Systolic blood pressure136mm[Hg]S
2026-05-29Diastolic blood pressure76mm[Hg]S
2026-05-29Heart rate74/minS
2026-05-29Respiratory rate16/minS
2026-05-29Body temperature36.7CelS
2026-05-29Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-08-14Body height188cmS
2026-08-14Body weight92.5kgS
2026-08-14Body mass index (BMI) [Ratio]26.2kg/m2S
2026-08-14Systolic blood pressure134mm[Hg]S
2026-08-14Diastolic blood pressure74mm[Hg]S
2026-08-14Heart rate72/minS
2026-08-14Respiratory rate16/minS
2026-08-14Body temperature36.6CelS
2026-08-14Oxygen saturation in Arterial blood by Pulse oximetry96%S
2026-04-24Body height188cmS
2026-04-24Body weight94.2kgS
2026-04-24Body mass index (BMI) [Ratio]26.7kg/m2S
2026-04-24Systolic blood pressure138mm[Hg]S
2026-04-24Diastolic blood pressure76mm[Hg]S
2026-04-24Heart rate75/minS
2026-04-24Respiratory rate16/minS
2026-04-24Body temperature36.6CelS
2026-04-24Oxygen saturation in Arterial blood by Pulse oximetry95%S

Encounters

DatePurposeStatusProvenance
2026-02-27Primary care new-patient visit for diabetes, lightheadedness on standing, and glaucoma follow-upfinishedS
2026-03-27Endocrinology consultation for diabetes and autonomic neuropathyfinishedS
2026-05-29Three-month diabetes, blood pressure, and eye pressure reviewfinishedS
2026-08-14Six-month diabetes review with glaucoma imagingfinishedS
2026-04-24Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Increase metformin to 1000 mg twice daily and set an individualized HbA1c goal below 7.5%; avoid insulin and sulfonylureas while autonomic neuropathy may blunt warning symptoms of hypoglycemiacompletedGL-ADA-2025, GL-CMID-2026S
Endocrinology consultation to confirm diabetic autonomic neuropathy as the cause of orthostatic hypotension, reconsider the earlier Shy-Drager label, and choose add-on glucose-lowering therapycompletedGL-ADA-2025S
Treat neurogenic orthostatic hypotension: stand up in stages, raise the head of the bed, use waist-high compression, drink 2 liters of fluid a day, then midodrine with the last dose at least four hours before bed; check supine blood pressure at each visitcompletedGL-ADA-2025S
Check HbA1c every three months until at goal, a basic metabolic panel, UACR, and lipids each year, lipids 4 to 12 weeks after starting a statin, and vitamin B12 periodically on metformincompletedGL-CMID-2026, GL-ADA-2025S
Examine the feet at every visit because of sensory loss; daily self-inspection and protective footwearcompletedGL-ADA-2025, GL-CMID-2026S
Coordinate glaucoma care with the eye clinic: add dorzolamide to latanoprost, check pressure at each visit, and repeat OCT and visual fields every six months; avoid timolol and brimonidine because of bradycardia, bronchospasm, and low blood pressurecompletedGL-AAO-POAG-2025, GL-CMID-2026S
Annual dilated eye examination for diabetic retinopathy; low-vision rehabilitation and home lighting reviewcompletedGL-ADA-2025, GL-AAO-POAG-2025S
Start atorvastatin 40 mg; give PCV20 and recombinant zoster vaccinescompletedGL-ADA-2025S

Goals

GoalTargetStatusOutcomeProvenance
Reach an HbA1c below 7.5% without hypoglycemia by the six-month review2026-08-14completedHbA1c fell from 8.6% to 7.3% with no hypoglycemiaS
No falls and a standing systolic pressure of 100 mm Hg or more by the six-month review2026-08-14completedNo falls since the second visit; 134/74 seated and 120/70 standing on midodrineS
Lower intraocular pressure to 16 mm Hg or less in each eye by the three-month review2026-05-29completedPressure 15 mm Hg right and 16 mm Hg left at three monthsS
LDL cholesterol below 70 mg/dL by the six-month review2026-08-14activeLDL 74 mg/dL at three months; recheck at the annual visitS

Functional Status

Mental Status